Studies have suggested the pivotal role of T helper type 1 (Th1) -related cytokines on the outcome of hepatitis C virus (HCV) infection. Nevertheless, the role of different interleukin-17 (IL-17) -secreting T cells on chronic hepatitis C (CHC) is less clear. Here, the in vivo IL-1b, IL-6, and IL-17 levels were positively correlated with both alanine transaminase (ALT) levels and hepatic lesions. When compared with the control group, CHC patients showed a lower proportion of IL-17-secreting (CD4 + and CD8 + ) T cells cap- ) T-cell phenotypes was positively associated with plasma CD14 levels. Finally, elevated levels of circulating CD14 were detected among CHC patients with extensive liver damage. In summary, although preliminary, our results suggest that a balance between different IL-17-producing T cells, associated with peripheral levels of CD14, may be a progress marker for liver disease in chronically HCV-infected patients.
Summary
Studies have suggested the pivotal role of T helper type 1 (Th1) -related cytokines on the outcome of hepatitis C virus (HCV) infection. Nevertheless, the role of different interleukin-17 (IL-17) -secreting T cells on chronic hepatitis C (CHC) is less clear. Here, the in vivo IL-1b, IL-6, and IL-17 levels were positively correlated with both alanine transaminase (ALT) levels and hepatic lesions. When compared with the control group, CHC patients showed a lower proportion of IL-17-secreting (CD4 + and CD8 + ) T cells capable of simultaneously producing IL-21. Moreover, the percentage of IL-10-secreting Th17 cells was also lower in CHC patients. Notably, advanced liver lesions were observed among those patients with lower percentage levels of IL-17-producing T cells positive for IL-21, interferon-c (IFN-c) and IL-10.
In contrast, the severity of hepatic damage was associated with peripheral single IL-17 + T cells. 
Introduction
Hepatitis C virus (HCV) infects more than 170 million people worldwide and causes chronic hepatitis in over 85% of patients, a clinical condition that can progress to cirrhosis and liver cancer, resulting in hepatic transplantation. 1 Several studies have indicated that either spontaneous cure after the acute phase or the outcome of a chronic phase of the disease depends on the immune response of HCV-infected patients.
Typically, the acute immune response to HCV infection involves the production of interferons a/b (IFN-a/b) by HCV-infected hepatocytes and innate immune cells.
This leads to interferon-induced transcription of genes whose main function is to reduce virus replication in the host cell. 2 In approximately 20% of patients, these interferons assist in the T-cell-dependent immune response capable of eliminating HCV, which resolves the disease. [3] [4] [5] In terms of the T-cell phenotype, HCV-specific T helper type 1 (Th1) and T CD8 + cells are involved in the control of viral replication. [5] [6] [7] [8] Some studies have demonstrated that low frequency of HCV-specific interleukin-2 (IL-2) and IFN-c-producing CD4 + T cells, as well as poor CD8 + T-cell-dependent cytotoxicity, coincides with persistent viral replication and progression to the chronic phase of the disease. [9] [10] [11] [12] [13] 
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hyporesponsiveness of these HCV-specific T lymphocytes has been related to the elevated expression of cell exhaustion markers, such as PD-1 and Tim-3 molecules. [14] [15] [16] Moreover, the maintenance of these dysfunctional T cells has also been associated with high levels of HCV-specific galectina-9 + Treg cells. 16 More recently, Th17 cells have also been implicated in the HCV infection. Elevated prevalence of peripheral IL-17-secreting CD4 + T cells was detected in patients with spontaneous resolution of infection after the acute phase. 6, 8 Even in the chronic phase, the presence of peripheral HCV-specific IL-17 + CD4 + T cells was associated with better outcomes in terms of liver damage. 16 On the other hand, the study by Lee et al. 17 found intense hepatic fibrosis associated with liver-infiltrating Th17 cells. Further, Chang et al.
18 demonstrated a positive correlation between the percentage of peripheral Th17 cells and plasmatic levels of alanine transaminase (ALT). These apparently conflicting findings may actually reflect the complex biology of T cells that produce IL-17.
The Th17 cells not only secrete IL-17, but also IL-22, IL-21 and even IFN-c, a classical cytokine produced by both Th1 and Tc-1 cells. 19 In the context of chronic hepatitis C (CHC), for example, dual IL-17 and IFN-c-producing CD8 + T cells were associated with a better prognosis for liver disease. 20 Moreover, IL-21-producing Th17 cells during the acute phase have been convincingly linked to disease resolution and HCV clearance. 21 These authors observed a direct correlation between IL-21 levels and polyfunctional HCV-specific CD8 + T cells, identified by IFN-c production and lower PD-1 and Tim-3 expression. 16, 21 Altogether, these results suggest that protective or deleterious involvement of IL-17-secreting T cells may depend on the cytokine arrays produced by these cells in response to HCV. However, even taking into account these findings, the determination of the relationship between different Th17 cell subsets and the outcome of liver disease in CHC patients, which was the objective of this study, remains unclear.
Materials and methods

Patients and control subjects
This cross-sectional study included 40 patients with CHC, genotype 1, from the Gastroenterology & Hepatology Division of the Internal Medicine Department at Gaffr ee e Guinle Hospital/UNIRIO. HCV infection was diagnosed based on the presence of serum antibodies against HCV and detectable serum HCV RNA (real-time PCR). All patients with CHC had undergone a biochemical assessment, such as plasmatic levels of ALT. Of note, despite the great variation in the time since HCV diagnosis (4-28 years), the majority of patients in our study (> 80%) had a diagnosis of infection between 9 and 15 years.
Healthy, age and sex-matched controls (n = 30), seronegative for hepatitis B virus HBV, human T-lymphotropic virus and HIV were also recruited to the study. Additionally, subjects were excluded if they had a history of excessive alcohol intake and immunosuppressive drug use, as well as autoimmune diseases. Among CHC patients, 30 were naive for HCV treatment, and 10 had previously failed anti-HCV therapy with pegylated IFN/ribavirin (at least 6 months before entering the study). In CHC patients, the level of hepatic fibrosis was determined from liver biopsies and scored using the Metavir scale. In the present study, the Metavir-stage was no (F0)/mild (F1) fibrosis in 20/40 and moderate (F2)/severe (F3) fibrosis in 20/40 patients.
After a complete description of the study for participants, written informed consent was obtained from each individual. The study was approved by the Ethics Committee for Research on Human Subjects of the Federal University of the State of Rio de Janeiro (UNIRIO).
Cell cultures, plasmas and stimuli
The plasmas from all subjects were frozen (À70°C) for subsequent cytokine and soluble CD14 analysis. To analyse cytokine production of T cells, whole blood cells were kept in 24-well flat-bottom microtitre plates and stimulated for 4 hr with PMA (20 ng/ml) plus ionomycin (600 ng/ml) in the presence of brefeldin A (10 lg/ml). The cells were maintained at 37°in a humidified 5% CO 2 incubator.
Flow cytometry analysis
Mouse anti-human monoclonal antibodies (mAbs) for CD3-phycoerythrin (PE), CD4-FITC, CD8-FITC, IL-21-allophycocyanin (APC), IFN-c-PE-Cy7, IL-17-PE, IL-10-APC, and all isotype control antibodies were purchased from BD Bioscience (San Diego, CA), and used to characterize the different T-cell phenotypes. Briefly, previously stimulated blood samples were incubated with various combinations of the aforementioned mAbs for 30 min at room temperature in the dark, according to the instructions of the manufacturer. Red cells were lysed (lysis buffer; eBioscience, San Diego, CA), washed with PBS containing 1% BSA and permeabilization was performed using incubating cells with Cytofix/Cytoperm solution (BD Pharmingen, San Diego, CA) at 4°for 20 min. The mAbs for intracellular staining (IL-21-APC, IFN-c-PECy7, IL-10-APC, IL-17-PE) were added in different combinations and incubated for 30 min at 4°. The cells were acquired at Accuri C6 (Accuri TM , Ann Arbor, MI) and analysed using Cflow (Accuri TM ). Isotype control antibodies and single-stained samples were used to periodically check the settings and gates on the flow cytometer. After acquisition of 100 000 events, lymphocytes were gated based on forward and side scatter properties after the exclusion of dead cells and doublets.
Quantification of plasmatic levels of cytokines and soluble CD14
The quantification of cytokines in the plasmas was performed using OptEIA ELISA kits (BD Pharmingen), according to the manufacturer's instructions. Briefly, each assay was carried out using pairs of mAbs targeting human IL-10, IL-1b, IL-6, IFN-c and IL-17. The reaction was revealed with streptavidin-horseradish peroxidase, using 3Á3 0 , 5Á5 0 -tetramethyl-benzidine as a substrate. Recombinant human cytokines, at concentrations ranging from 3Á5 to 500 pg/ml, were used to construct standard curves. The plasmatic levels of soluble CD14 (sCD14) were determined using the ELISA technique with Quantikine Human CD14 Immunoassay (R&D, Minneapolis, MN) according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was carried out using PRISM 5.0 software (GraphPad Software, San Diego, CA, USA). The non-parametric Mann-Whitney U-test and the Student's t-test were applied to determine whether the two groups were statistically different for non-parametric and parametric variables, respectively. Spearman's correlations were applied to analyse either relationship between the immunological events and clinical parameters in CHC patients. Significance in all experiments was defined as P < 0Á05.
Results
Characteristics of CHC patients, in vivo cytokine dosage and the relationship with clinical parameters For our study, viraemic CHC patients (25 women and 15 men), medication-free for HCV at the time of blood sampling, were recruited and their immunological profiles were correlated with clinical parameters. Although 10/40 CHC patients had failed prior pegylated IFN/ribavirin therapy, no difference was observed either in terms of ALT levels or the time elapsed since HCV diagnosis [failed (15 AE 7Á8 years) 9 naive (11Á3 AE 6Á1 years), P = 0Á7123]. As expected, the plasma ALT levels were lower in the control group (Table 1) . Concerning the in vivo cytokine dosage, IL-1b, IL-6 and IL-17 levels were significantly higher in the peripheral blood of CHC patients than in the control group (Fig. 1a) . No difference was observed in terms of IL-10 and IFN-c concentrations (Fig. 1a) . IL-1b, IL-6 and IL-17 concentrations were positively correlated with ALT levels (Fig. 1b) and were detected at higher levels among CHC patients with advanced hepatic lesions, determined according to the Metavir scale (Fig. 1c) . By contrast, no difference was observed with regard to IL-10 levels and liver fibrosis (Fig. 1c) . Notably, no significant difference was observed in terms of plasma cytokine levels between naive and failed HCV-infected patients. Additionally, in the control group, ALT levels were not significantly correlated with peripheral cytokines (data not shown).
The frequency of IL-17-producing T-cell subsets in chronically HCV-infected patients and their relationship with hepatic function
Th17 cells have been implicated in either the protection or pathogenesis of HCV infection. 17, 18 Here, elevated cytokine levels related to Th17-mediated responses (IL-17, IL-1b and IL-6) were not only dosed in the peripheral blood of CHC patients, but their levels were associated with clinical and laboratory parameters of damaged liver function. Given that IL-17-producing T cells present a relatively heterogeneous population, our next objective was to determine the proportion of different IL-17-secreting CD4 + and CD8 + T-cell subsets in CHC patients and correlate these with the occurrence of hepatic lesions and peripheral enzyme levels. As shown in Fig. 2 , and following the Th17-like phenotypes and chronic hepatitis C Cytokines (pg/ml) representative flow cytometry dot-plots showing the gating strategy for CD4 + (Fig. 2a ) and CD8 + (Fig. 2b) T cells, the percentage of IL-17 + (CD4 + and CD8 + ) T cells able to produce IL-21 was significantly lower in CHC patients when compared with the control group. The same phenomenon was observed for IL-10-producing Th17 cells (Fig. 2a) and single IFN-c-producing (CD4 + and CD8 + ) T cells (data not shown). On the other hand, the proportion of single IL-17 + (CD4 + and CD8 + ) T cells was higher among CHC patients (Fig. 2) . We observed no difference in terms of the dual IL-17 and IFN-c-producing (CD4 + and CD8 + ) T cells (Fig. 2) . Notably, in terms of the percentage of different IL-17-secreting T cells, no difference was observed between naive and therapy failed HCV patients (data not shown).
Among CHC patients, the frequency of CD4 + (Fig. 3a ) and CD8 + (Fig. 3b) T cells that produce IL-17 in association with IL-21 or IFN-c was negatively correlated with serum levels of hepatic enzymes (Fig. 3a,b) . Furthermore, the proportion of these T-cell subsets, and those able to simultaneously produce IL-17 and IL-10, were detected at lower frequencies in CHC patients with advanced hepatic lesions (Fig. 4a,b) . In contrast, the proportion of single IL-17-producing CD4 + and CD8 + T cells, negative for IL-21 and IFN-c in CHC patients, was mainly detected in patients with higher levels of liver fibrosis (Fig. 4a,b) , and was directly correlated with ALT concentrations (Fig. 3a,  b) . Finally, although no significant relationship was observed between plasma ALT levels and single IFN-cproducing CD4 + and CD8 + T cells, classically named Th1 and Tc-1 cells, 5 their frequency was lower in CHC patients with higher Metavir scores (data not shown).
Higher bacterial translocation associated with IL-17 positive T cells and hepatic lesions was observed in CHC patients
Much evidence has suggested that elevated plasmatic levels of soluble CD14 (sCD14) are indicative of bacterial translocation. 22 Recent studies have demonstrated a relationship between sCD14 and hepatic disease outcomes in chronically HCV-infected individuals. [23] [24] [25] [26] In this study, sCD14 concentrations were not only elevated in plasma from naive and therapy failed CHC patients (Fig. 5a ), but higher levels were detected among those patients with elevated hepatic fibrosis (Fig. 5b) . Furthermore, sCD14 levels were positively correlated with either in vivo IL-1b, IL-6, IL-17 and IL-10 cytokines (Table 2) or single IL-17-producing (CD4 + and CD8 + ) T cells. Finally, ALT concentrations were also directly correlated with sCD14 levels (Table 2) .
Discussion
Hepatitis C virus infects approximately 3% of the global population, with 3-4 million new cases every year. 1 In the great majority of patients (up to 80%), HCV persists, leading to chronic hepatitis associated with liver fibrosis, cirrhosis and hepatocellular carcinoma. Given that HCV has few cytopathic effects on host cells, it is believed that the hepatic disease outcome is instead a result of immune behaviour in response to viral infection. Therefore, the identification of immune markers involved in the prognosis of the disease is pivotal for the development of vaccines and new therapeutic targets. This study, although preliminary, shows data that help to understand the differential role of IL-17-secreting T-cell subsets on the progression of liver disease in CHC patients. Here, the in vivo IL-1b, IL-6 and IL-17 levels were associated with both plasma ALT levels and the degree of liver fibrosis in CHC patients. The absence of a correlation between this transaminase and peripheral cytokines in the control group suggests that altered plasma cytokines in patients are associated with hepatic viral infection. French et al. 23 found high peripheral IL-6 levels in HCV-infected patients with severe liver damage. Moreover, genetic polymorphism for IL-6 has also been associated with fast progression of liver damage following HCV infection. 27, 28 Although different cells can produce IL-1b and IL-6, these cytokines are mainly produced by innate immunity, such as liver macrophages, the Kupffer cells. 29 Hyperresponsiveness of Kupffer cells to microbial antigens has been observed in CHC, a condition that contributes to liver inflammation. 30, 31 The relationship between persistent activation of Kupffer cells by microbial antigens likelipopolysaccharides (LPS), and CHC disease progression should be linked to fibrosis promotion by stellate cells in response to Kupffer cell-derived IL-1b and IL-6 cytokines. 23, 32 Despite innate immune origin, IL-1b, IL-6 and, principally, IL-17 can also be produced by some T cells, particularly the Th17 phenotype. 33 Nevertheless, IL-17-secreting T cells appear to present a relatively heterogeneous population. Typically, Th17 cells produce IL-17, IL-21 and IL-22. 34 However, IL-6 or IFN-c, and even IL-10, can be produced by IL-17-secreting CD4 + T cells. 33, [35] [36] [37] In addition, IL-17-producing CD8 + T cells, called Tc-17 cells, have also been found in humans. 38 In the early stages of the disease, for example, the production of IL-21 by Th17 cells has been convincingly linked to protection and spontaneous healing after the acute phase of HCV infection. 16, 21, 39 In our CHC patients, the proportion of this cell subset could also be related to better liver disease outcomes, as its percentage was higher among patients with lower hepatic lesions and plasmatic ALT levels. Although Feng et al. 21 have not found any association between the frequency of IL-21 + CD4 + T cells with the serum levels of ALT and aspartate transaminase (AST) enzymes, patients recruited to this study had almost normal transaminase levels, different from our cohort, where 27/40 patients had higher ALT concentrations.
Interestingly, IL-21-producing Tc-17 cells were also observed among CHC patients with less liver damage. To our knowledge, this is the first report that demonstrates the correlation between IL-21-producing CD8 + T cells and liver disease prognosis in CHC patients.
The protector effects of IL-21 in HCV infection might be associated with its ability to induce HCV-specific CD8 + T-cell proliferation and reduce the expression of PD-1 and Tim-3, both markers of dysfunctional cells. 16, [40] [41] [42] [43] [44] [45] [46] In addition to Th17 cells, IL-21 is also produced by helper follicular T (Tfh) cells, a CD4 + T-cell line known to help B lymphocytes to produce highly efficient antibodies. 47, 48 Nevertheless, the contribution of Tfh cells to HCV protection is controversial, given that spontaneous resolution of infection after the acute phase appears to be independent of antibody production. [49] [50] [51] Nevertheless, we will investigate the contribution of IL-21 produced by Tfh cells to CHC outcomes.
Some studies have demonstrated the ability of Th17 cells to produce IFN-c. 35 Similar to IL-21-positive Th17 cells, the percentage of peripheral CD4 + and CD8 + T cells that produce both IL-17 and IFN-c was strongly associated with a better prognosis in CHC patients. Billerbeck et al. 20 also found a positive association between the prevalence of IL-17 + IFN-c + CD8 + T cells with better outcomes in CHC patients. Further, the proportion of single IFN-c-producing CD4 + and CD8 + T lymphocytes, which include Th1 and Tc-1 cells, was lower among CHC patients with higher liver fibrosis scores (data not shown). Indeed, early IFN-c production by HCV-specific T cells is involved in protecting against HCV. 5, 16, 21, 52 On the other hand, the proportion of single IL-17-producing CD4 + and CD8 + T cells was strongly linked to disease severity in CHC patients. Th17 cells are enriched in both liver and peripheral blood of CHC patients. 18, 53, 54 This event was associated with elevated IL-23 production by monocytes from those patients. 55 In the context of autoimmune diseases, IL-23, IL-1b and IL-6 cytokines, in the absence of transforming growth factor-b, favours pathogenic Th17 differentiation. 33, 35, 37 Although we did not measure transforming growth factor-b and IL-23, higher levels of IL-1b and IL-6, as well as IL-17 were detected in the plasma of CHC patients than in the control group. Even given the contribution of different immune cells to the production of these in vivo cytokines, dendritic cell-derived IL-1b and IL-6 favour the differentiation of human CD4 + T cells into pathogenic Th17 cells. 35 Furthermore, levels of IL-6 and IL-17 were positively associated with single IL-17-secreting (CD4 + and CD8 + ) T cells (data not shown). In agreement with our study, the study by Chang et al. 18 showed that plasmatic levels of IL-17 were directly associated with both hepatic and peripheral Th17 cells and ALT concentrations. Collectively these findings suggest the pathogenic involvement of single IL-17-producing T cells in CHC outcomes.
Finally, a higher percentage of IL-10-secreting Th17 cells was observed in those patients with lower hepatic lesions. In humans, IL-10-secreting Th17 subsets have been associated with tissue protection during 
The plasmatic levels of soluble CD14 (sCD14) were quantified in patients with chronic hepatitis C (n = 40) and were compared with alanine transaminase (ALT) levels and different interleukin-17 (IL-17)-producing CD4 + and CD8 + T-cell phenotypes.
Significance was defined as P < 0Á05 and significant differences are highlighted in bold.
ª 2017 John Wiley & Sons Ltd, Immunology, 151, 167-176 inflammatory reactions following viral infection and autoimmune response, [35] [36] [37] 56, 57 suggesting a protective role for these non-classical regulatory T cells in liver disease in chronically HCV-infected subjects.
Elevated in vivo CD14 levels were detected in the plasma of CHC patients with advanced liver disease. The CD14 molecule is expressed mainly in the membranes of phagocytes connected to a glycosylphosphatylinositol anchor, and acts as a co-receptor for LPS. 58 The soluble form of the CD14 molecule is usually released following the activation of phagocytes by different microbial stimuli, but particularly by LPS. 59 Therefore, some researchers believe that sCD14 is a more relevant biomarker of microbial translocation than the LPS dosage itself, as systemic levels of CD14 better reflect the sensitivity of the response of phagocytes to this standard microbe. 60, 61 Here, the sCD14 were not only higher among CHC patients, but their levels were positively associated with in vivo IL-1b, IL-6 and IL-17 concentrations. Notably, among all T-cell subsets, the levels of sCD14 were positively associated with single IL-17-secreting T cells. Indeed, some studies have found higher sCD14 and LPS from Escherichia coli in the peripheral blood of CHC patients, when compared with control subjects. 61, 62 Further, sCD14 levels were related to plasma ALT and AST concentrations, and severe liver damage. 26, 63 Elevated bacterial translocation in CHC patients is probably the consequence of an inability of Kupffer cells to efficiently clean microbial antigens that reach the liver through the portal vein. 61, 63, 64 Conclusions Collectively, our results, although preliminary, suggest that peripheral CD4 + and CD8 + T cells that produce IL-17 in the absence of IL-21 and IFN-c, play a pathogenic role in CHC patients. Moreover, the close relationship between sCD14 and the frequency of single IL-17-producing T cells with liver damage, reveals the negative impact exerted by microbial translocation on liver disease progression in chronically HCV-infected patients.
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